| Monkeypox virus infection in humans across 16 countries—April–June 2022 JP Thornhill, S Barkati, S Walmsley, J Rockstroh, A Antinori, LB Harrison, ... New England Journal of Medicine 387 (8), 679-691, 2022 | 1688 | 2022 |
| Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy MT May, M Gompels, V Delpech, K Porter, C Orkin, S Kegg, P Hay, ... Aids 28 (8), 1193-1202, 2014 | 718 | 2014 |
| Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti, C Orkin, M Bloch, ... The Lancet 381 (9868), 735-743, 2013 | 653 | 2013 |
| Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials PE Sax, KM Erlandson, JE Lake, GA Mccomsey, C Orkin, S Esser, ... Clinical Infectious Diseases 71 (6), 1379-1389, 2020 | 607 | 2020 |
| Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals D Corti, JPM Langedijk, A Hinz, MS Seaman, F Vanzetta, ... PloS one 5 (1), e8805, 2010 | 523 | 2010 |
| Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study HJ Stellbrink, C Orkin, JR Arribas, J Compston, J Gerstoft, ... Clinical Infectious Diseases 51 (8), 963-972, 2010 | 483 | 2010 |
| Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study M May, M Gompels, V Delpech, K Porter, F Post, M Johnson, D Dunn, ... Bmj 343, 2011 | 479 | 2011 |
| British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow … Writing Group, I Williams, D Churchill, J Anderson, M Boffito, M Bower, ... HIV medicine 15, 1-6, 2014 | 419 | 2014 |
| Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label … JK Rockstroh, M Nelson, C Katlama, J Lalezari, J Mallolas, M Bloch, ... The lancet HIV 2 (8), e319-e327, 2015 | 409 | 2015 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 406 | 2019 |
| Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind … J Gallant, A Lazzarin, A Mills, C Orkin, D Podzamczer, P Tebas, PM Girard, ... The Lancet 390 (10107), 2063-2072, 2017 | 378 | 2017 |
| Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active … A Mills, JR Arribas, J Andrade-Villanueva, G DiPerri, J Van Lunzen, ... The Lancet Infectious Diseases 16 (1), 43-52, 2016 | 368 | 2016 |
| Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection C Orkin, K Arasteh, M Górgolas Hernández-Mora, V Pokrovsky, ... New England Journal of Medicine 382 (12), 1124-1135, 2020 | 353 | 2020 |
| Monkeypox O Mitjà, D Ogoina, BK Titanji, C Galvan, JJ Muyembe, M Marks, CM Orkin The Lancet 401 (10370), 60-74, 2023 | 252 | 2023 |
| Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naive patients in the ARTEMIS trial C Orkin, E DeJesus, H Khanlou, A Stoehr, K Supparatpinyo, ... HIV medicine 14 (1), 49-59, 2013 | 249 | 2013 |
| Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study EM Berkowitz, G Moyle, HJ Stellbrink, D Schürmann, S Kegg, M Stoll, ... The Journal of infectious diseases 211 (8), 1279-1287, 2015 | 240 | 2015 |
| Mpox in people with advanced HIV infection: a global case series O Mitjà, A Alemany, M Marks, JIL Mora, JC Rodríguez-Aldama, MST Silva, ... The Lancet 401 (10380), 939-949, 2023 | 237 | 2023 |
| British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011 D Asboe, C Aitken, M Boffito, C Booth, P Cane, A Fakoya, AM Geretti, ... HIV med 13 (1), 1-44, 2012 | 236 | 2012 |
| Brief communication: rituximab in HIV-associated multicentric Castleman disease M Bower, T Powles, S Williams, TN Davis, M Atkins, S Montoto, C Orkin, ... Annals of internal medicine 147 (12), 836-839, 2007 | 234 | 2007 |
| Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study JM Molina, C Orkin, DM Iser, FX Zamora, M Nelson, C Stephan, ... The Lancet 385 (9973), 1098-1106, 2015 | 226 | 2015 |
